



Catherine T. Frenette, M.D.  
Medical Director of Liver Transplantation  
Scripps Center for Organ Transplantation  
Scripps Clinic – Scripps Green Hospital  
10666 N. Torrey Pines Rd, Suite N200  
La Jolla, CA 92037  
Email: [Frenette.Catherine@scrippshealth.org](mailto:Frenette.Catherine@scrippshealth.org)  
Telephone: (858) 554-4310  
Fax: (858) 554-3009

July 19<sup>th</sup>, 2016

Dear Dr. Fang-Fang Ji, Science Editor:

We would like to thank the reviewers for their critical review of our manuscript. Reviewer #1's comments and suggestions are listed below along with our point-to-point responses.

1. Throughout the text, the authors describes many about their published case report (especially in Introduction section with figure). There is possibility of duplication, thus the authors should minimize the statement of their published case report.

**RESPONSE:** The recently published case report was mentioned briefly and referenced to serve as the basis for this case-based minireview. We have further minimized the referenced text as suggested.

2. Please state with more focus on pulmonary Cx of TACE. HCC and TACE subtitle sections are too lengthy and need to be shorten and moved into the Introduction section, because most leaders who are interested in this topic knows well those descriptions.

**RESPONSE:** We have ensured that the minireview focuses only on the pulmonary complication of TACE for HCC. The HCC and TACE sections were written to provide sufficient background for a broad range of audience, including experts in other fields who otherwise may not be fully familiar with HCC and TACE.

3. Some schematic figures would help readers to understand the author's manuscript.

**RESPONSE:** Although additional schematic figures would be potentially helpful, we respectfully do not believe that they are necessary. The readers are referred to referenced excellent review articles that are fully dedicated to the mechanisms and methodology of TACE.

4. What about mortality rate of pulmonary Cx after TACE?

**RESPONSE:** The mortality rate of pulmonary complications after TACE is listed in Table I, where applicable.

5. The authors mentioned that 70% of patients who received additional embolization of RIPA showed pulmonary complications. These 70% complications caused significant clinical sequelae? Usually additional embolization of parasiting artery (such as RIPA, int.mammary A...) is well established treatment. The authors need to describe more about this topic with other references.

**RESPONSE:** We have clarified the text. Additional references have been added regarding RIPA. Changes have been highlighted in the corresponding paragraph.

6. The authors mentioned that TACE-mediated lung metastasis. Is this reliable theory? I think that lung metastasis is not associated with TACE itself but associate with vessel (PV, HV) invasion of HCC. This need to be verified.

**RESPONSE:** We have clarified our text regarding the current state of controversy in this area, with additional references. Changes have been highlighted in the corresponding paragraph.

Thank you for the opportunity to contribute this minireview to the journal.

Sincerely,

Catherine T. Frenette, M.D.